GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poseida Therapeutics Inc (NAS:PSTX) » Definitions » Cash Flow from Investing

Poseida Therapeutics (Poseida Therapeutics) Cash Flow from Investing : $39.13 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Poseida Therapeutics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, Poseida Therapeutics spent $0.31 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $21.98 Mil on purchasing investments. It gained $70.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Poseida Therapeutics gained $47.71 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


Poseida Therapeutics Cash Flow from Investing Historical Data

The historical data trend for Poseida Therapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poseida Therapeutics Cash Flow from Investing Chart

Poseida Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial -42.46 -204.43 222.38 -203.33 39.13

Poseida Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -85.89 -4.42 43.07 -47.24 47.71

Poseida Therapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Poseida Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Poseida Therapeutics's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $39.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Poseida Therapeutics  (NAS:PSTX) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Poseida Therapeutics's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $-0.31 Mil. It means Poseida Therapeutics spent $0.31 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Poseida Therapeutics's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Poseida Therapeutics gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Poseida Therapeutics's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Poseida Therapeutics spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Poseida Therapeutics's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Poseida Therapeutics gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Poseida Therapeutics's purchase of investment for the three months ended in Dec. 2023 was $-21.98 Mil. It means Poseida Therapeutics spent {stock_data.stock.currency_symbol}}21.98 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Poseida Therapeutics's sale of investment for the three months ended in Dec. 2023 was $70.00 Mil. It means Poseida Therapeutics gained $70.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Poseida Therapeutics's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means Poseida Therapeutics paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Poseida Therapeutics's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means Poseida Therapeutics paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Poseida Therapeutics's cash from other investing activities for the three months ended in Dec. 2023 was $0.00 Mil. It means Poseida Therapeutics paid $0.00 Mil for other investing activities.


Poseida Therapeutics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Poseida Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Poseida Therapeutics (Poseida Therapeutics) Business Description

Traded in Other Exchanges
Address
9390 Towne Centre Drive, Suite 200, San Diego, CA, USA, 92121
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
Executives
John P. Schmid director 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Luke Corning director 614 DAVIS STREET, EVANSTON IL 60201
Marcea Bland Lloyd director 9360 TOWNE CENTRE DRIVE, SUITE 110, SAN DIEGO CA 92121
Charles M Baum director C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Cynthia Collins director 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Rafael Amado director 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Kristin Yarema officer: President, Cell Therapy C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080
Malin Life Sciences Holdings Ltd 10 percent owner 2 HARBOUR SQUARE, CROFTON ROAD, DUN LAOGHAIRE, CO, DUBLIN L2 ----
Eric Ostertag director, 10 percent owner, officer: Chief Executive Officer C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121
Kerry D. Ingalls officer: Chief Operating Officer C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Brent Warner officer: President, Gene Therapy C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Matthew A. Spear officer: Chief Medical Officer C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121
Harry J Leonhardt officer: GC & Chief Compliance Officer C/O HALOZYME THERAPEUTICS, INC., 11388 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121
David Hirsch director C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Sean Murphy director, 10 percent owner C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703